Literature DB >> 14754988

Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles.

Victor M Miller1, Cynthia M Gouvion, Beverly L Davidson, Henry L Paulson.   

Abstract

Tau and amyloid precursor protein (APP) are key proteins in the pathogenesis of sporadic and inherited Alzheimer's disease. Thus, developing ways to inhibit production of these proteins is of great research and therapeutic interest. The selective silencing of mutant alleles, moreover, represents an attractive strategy for treating inherited dementias and other dominantly inherited disorders. Here, using tau and APP as model targets, we describe an efficient method for producing small interfering RNA (siRNA) against essentially any targeted region of a gene. We then use this approach to develop siRNAs that display optimal allele-specific silencing against a well-characterized tau mutation (V337M) and the most widely studied APP mutation (APPsw). The allele-specific RNA duplexes identified by this method then served as templates for constructing short hairpin RNA (shRNA) plasmids that successfully silenced mutant tau or APP alleles. These plasmids should prove useful in experimental and therapeutic studies of Alzheimer's disease. Our results suggest guiding principles for the production of allele-specific siRNA, and the general method described here should facilitate the production of gene-specific siRNAs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754988      PMCID: PMC373334          DOI: 10.1093/nar/gkh208

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  29 in total

1.  A complex of the bacteriophage T7 primase-helicase and DNA polymerase directs primer utilization.

Authors:  M Kato; D N Frick; J Lee; S Tabor; C C Richardson; T Ellenberger
Journal:  J Biol Chem       Date:  2001-03-28       Impact factor: 5.157

Review 2.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase.

Authors:  Olivier Donzé; Didier Picard
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

Review 4.  gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

Authors:  Sangram S Sisodia; Peter H St George-Hyslop
Journal:  Nat Rev Neurosci       Date:  2002-04       Impact factor: 34.870

5.  RNAi in human cells: basic structural and functional features of small interfering RNA.

Authors:  Ya-Lin Chiu; Tariq M Rana
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

Review 6.  Gene silencing in mammals by small interfering RNAs.

Authors:  Michael T McManus; Phillip A Sharp
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

7.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

8.  Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype.

Authors:  H Houlden; M Baker; H R Morris; N MacDonald; S Pickering-Brown; J Adamson; A J Lees; M N Rossor; N P Quinn; A Kertesz; M N Khan; J Hardy; P L Lantos; P St George-Hyslop; D G Munoz; D Mann; A E Lang; C Bergeron; E H Bigio; I Litvan; K P Bhatia; D Dickson; N W Wood; M Hutton
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

9.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

Review 10.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

View more
  49 in total

Review 1.  RNA interference in neuroscience: progress and challenges.

Authors:  Victor M Miller; Henry L Paulson; Pedro Gonzalez-Alegre
Journal:  Cell Mol Neurobiol       Date:  2005-12       Impact factor: 5.046

Review 2.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 3.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

4.  RNA interference: A futuristic tool and its therapeutic applications.

Authors:  Anghesom Ambesajir; Atul Kaushik; Jeevan J Kaushik; Sham T Petros
Journal:  Saudi J Biol Sci       Date:  2012-08-17       Impact factor: 4.219

Review 5.  RNA interference and nonviral targeted gene therapy of experimental brain cancer.

Authors:  Ruben J Boado
Journal:  NeuroRx       Date:  2005-01

6.  Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models.

Authors:  Kathryn H Morelli; Laurie B Griffin; Nettie K Pyne; Lindsay M Wallace; Allison M Fowler; Stephanie N Oprescu; Ryuichi Takase; Na Wei; Rebecca Meyer-Schuman; Dattatreya Mellacheruvu; Jacob O Kitzman; Samuel G Kocen; Timothy J Hines; Emily L Spaulding; James R Lupski; Alexey Nesvizhskii; Pedro Mancias; Ian J Butler; Xiang-Lei Yang; Ya-Ming Hou; Anthony Antonellis; Scott Q Harper; Robert W Burgess
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

7.  Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.

Authors:  J Kaplan; F S Kaplan; E M Shore
Journal:  Gene Ther       Date:  2011-10-20       Impact factor: 5.250

Review 8.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

Review 9.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 10.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.